Medical Gas Plasma Technology Combines with Antimelanoma Therapies and Promotes Immune-Checkpoint Therapy Responses.
B16F10
CAP
immuno-oncology
reactive oxygen species
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
11
07
2023
received:
17
05
2023
pubmed:
5
8
2023
medline:
5
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
Strategies to improve activity and selectivity are major goals in oncological drug development. Medical gas plasma therapy has been subject to intense research in dermatooncology recently. Based on partial gas ionization, this approach is exceptional in generating a variety of reactive oxygen species simultaneously that can be applied locally at the tumor side. It is hypothesized that combined gas plasma treatment can potentiate drug responses in the treatment of melanoma. Using a plasma jet approved as medical device in Europe, a systematic screening of 46 mitochondria-targeted drugs identifies five agents synergizing in vitro and in vivo. Increased intratumoral leucocyte infiltration points to immunomodulatory aspects of the treatment, motivating to investigate responses to immune checkpoint blockade in combination with plasma. Tumor growth is monitored based on bioluminescent imaging, and single-cell suspensions are retrieved from each tumor to characterize tumor-infiltrating leucocytes using multicolor flow cytometry. Gene expression profiling is done using a validated NanoString panel targeting 770 genes specifically designed for immuno-oncological research. Cell type abundancies are characterized from bulk RNA samples using the CIBERSORT computational framework. Collectively, the results indicate that local application of medical gas plasma technology synergizes with mitochondria-targeted drugs and anti-PD1 checkpoint therapy in treating melanoma.
Identifiants
pubmed: 37541287
doi: 10.1002/advs.202303183
pmc: PMC10558686
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2303183Subventions
Organisme : German Federal Ministry of Education and Research (BMBF)
ID : 03Z22DN11
Organisme : German Federal Ministry of Education and Research (BMBF)
ID : 03Z22Di1
Organisme : Gerhard-Domagk-Foundation (Greifswald, Germany)
Informations de copyright
© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.
Références
Nat Rev Clin Oncol. 2022 Feb;19(2):114-131
pubmed: 34819622
Nat Rev Clin Oncol. 2020 Nov;17(11):657-674
pubmed: 32699309
Oncoimmunology. 2020 Dec 29;10(1):1859731
pubmed: 33457077
Sci Rep. 2019 Sep 9;9(1):12891
pubmed: 31501494
Adv Sci (Weinh). 2019 Jan 28;6(6):1802062
pubmed: 30937272
Int J Mol Sci. 2017 Apr 19;18(4):
pubmed: 28422070
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Nat Commun. 2020 Apr 20;11(1):1897
pubmed: 32312968
Biochem Biophys Res Commun. 2016 May 13;473(4):1125-1132
pubmed: 27067049
Int J Med Sci. 2017 Sep 4;14(11):1101-1109
pubmed: 29104464
Vaccines (Basel). 2022 Oct 28;10(11):
pubmed: 36366323
Cancers (Basel). 2022 Jun 23;14(13):
pubmed: 35804869
Cells. 2022 Nov 18;11(22):
pubmed: 36429087
Oncogene. 2004 Apr 12;23(16):2891-906
pubmed: 15077152
Anticancer Res. 2019 May;39(5):2405-2413
pubmed: 31092433
Biointerphases. 2020 Nov 25;15(6):061008
pubmed: 33238712
Lancet Oncol. 2010 Dec;11(12):1149-59
pubmed: 21094089
Sci Rep. 2018 Aug 24;8(1):12734
pubmed: 30143716
Nat Med. 2019 May;25(5):744-750
pubmed: 31011206
Cell Death Dis. 2014 Feb 13;5:e1056
pubmed: 24525732
Oxid Med Cell Longev. 2021 Oct 27;2021:2990326
pubmed: 34745414
Cancers (Basel). 2020 Sep 09;12(9):
pubmed: 32917026
Leuk Lymphoma. 2021 Apr;62(4):810-818
pubmed: 33236943
PLoS One. 2016 Sep 01;11(9):e0160667
pubmed: 27584003
Cells. 2021 Oct 28;10(11):
pubmed: 34831159
J Invest Dermatol. 2021 Jan;141(1):23-31
pubmed: 32268150
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
pubmed: 19478820
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Mol Ther. 2015 Oct;23(10):1630-40
pubmed: 26112079
Cancers (Basel). 2021 Apr 01;13(7):
pubmed: 33915703
Sci Rep. 2017 Aug 16;7(1):8319
pubmed: 28814809
Cell Death Dis. 2018 Dec 5;9(12):1179
pubmed: 30518936
Oncol Rep. 2016 Oct;36(4):2268-74
pubmed: 27573888
Cancers (Basel). 2023 Jan 03;15(1):
pubmed: 36612315
Clin Cancer Res. 2011 Mar 15;17(6):1394-404
pubmed: 21220478
Int J Mol Sci. 2020 Feb 18;21(4):
pubmed: 32085661
Clin Cancer Res. 2018 Mar 15;24(6):1260-1270
pubmed: 29127120
Cancers (Basel). 2020 May 19;12(5):
pubmed: 32438553
Biomolecules. 2020 Jul 08;10(7):
pubmed: 32650505
Nat Med. 2019 Jul;25(7):1073-1081
pubmed: 31270502
Diagnostics (Basel). 2020 Apr 11;10(4):
pubmed: 32290487
Adv Sci (Weinh). 2021 Mar 08;8(10):2003395
pubmed: 34026437
Cell Death Dis. 2020 Jun 8;11(6):443
pubmed: 32513939
J Clin Oncol. 2011 Mar 1;29(7):909-16
pubmed: 21282543
Oncoimmunology. 2018 Jul 26;7(9):e1484978
pubmed: 30228954
Oxid Med Cell Longev. 2017;2017:4271065
pubmed: 28947928
Int J Cardiol. 2015 Apr 1;184:9-13
pubmed: 25705003
Pigment Cell Melanoma Res. 2014 Jul;27(4):525-39
pubmed: 24655414
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
EJC Suppl. 2013 Sep;11(2):97-105
pubmed: 26217118
Adv Sci (Weinh). 2023 Oct;10(28):e2303183
pubmed: 37541287
Free Radic Biol Med. 2021 Apr;166:187-200
pubmed: 33636332
Mol Cell. 2015 Jul 16;59(2):285-97
pubmed: 26118643
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2157-63
pubmed: 16100036
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
PLoS One. 2013 May 21;8(5):e64498
pubmed: 23704990
Sci Rep. 2021 Jan 8;11(1):136
pubmed: 33420228
Cancers (Basel). 2020 Jul 21;12(7):
pubmed: 32708225
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Cell. 2015 Sep 10;162(6):1271-85
pubmed: 26359985
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200708119
pubmed: 35901213
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Oncotarget. 2015 Oct 20;6(32):33382-96
pubmed: 26450902
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Cancers (Basel). 2018 Oct 23;10(11):
pubmed: 30360539
Pathol Int. 2018 Jul;68(7):442-443
pubmed: 29624784
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Nature. 2013 Feb 14;494(7436):251-5
pubmed: 23302800
Adv Sci (Weinh). 2020 Mar 30;7(10):1903438
pubmed: 32440479
Sci Rep. 2019 Jan 24;9(1):634
pubmed: 30679720
JAMA. 2011 Oct 12;306(14):1549-56
pubmed: 21990298
Free Radic Biol Med. 2017 Jul;108:904-917
pubmed: 28465262
Sci Rep. 2021 Jul 20;11(1):14788
pubmed: 34285268
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Br J Cancer. 2016 Feb 16;114(4):435-43
pubmed: 26882067
Sci Rep. 2021 Oct 19;11(1):20672
pubmed: 34667240